Haemonetics
295 hedge funds and large institutions have $4.36B invested in Haemonetics in 2023 Q4 according to their latest regulatory filings, with 37 funds opening new positions, 91 increasing their positions, 118 reducing their positions, and 36 closing their positions.
235% more call options, than puts
Call options by funds: $16M | Put options by funds: $4.78M
3% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 36
0.5% more ownership
Funds ownership: 100.03% → 100.53% (+0.5%)
0% less funds holding
Funds holding: 296 → 295 (-1)
4% less capital invested
Capital invested by funds: $4.55B → $4.36B (-$189M)
23% less repeat investments, than reductions
Existing positions increased: 91 | Existing positions reduced: 118
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$32.5M |
| 2 |
BlackRock
New York
|
+$22.3M |
| 3 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$21.2M |
| 4 |
Westfield Capital Management
Boston,
Massachusetts
|
+$13.1M |
| 5 |
Norges Bank
Oslo,
Norway
|
+$9.11M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$16M |
| 2 |
Fisher Asset Management
Camas,
Washington
|
-$13.1M |
| 3 |
Victory Capital Management
San Antonio,
Texas
|
-$13M |
| 4 |
CCM
Cinctive Capital Management
New York
|
-$12.5M |
| 5 |
LCP
LGT Capital Partners
Pfaeffikon,
Switzerland
|
-$10M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
LFA
326
LGT Financial Advisors
Dallas,
Texas
| – | -$2.78K | -31 | Closed |
|
327
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
| – | -$806 | -9 | Closed |
|
|
AAP
328
Arax Advisory Partners
Denver,
Colorado
| – | -$628 | -7 | Closed |
|
|
BAAM
329
Baker Avenue Asset Management
San Francisco,
California
| – | -$269 | -3 | Closed |
|
330
AssetMark Inc
Concord,
California
| – | -$90 | -1 | Closed |
|
HAE Hedge Fund Activity: Q4 2023 in Review
295 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Haemonetics (HAE) for Q4 2023, worth a combined $4.36B — down 4.1% from $4.55B a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new HAE positions and 36 closed out — a net gain of 1 holder — while 91 added to existing stakes and 118 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $32.5M. The largest seller was Millennium Management, cutting an estimated $16M.
- 295 institutional investors held Haemonetics (HAE) as of Q4 2023, down from 296 in Q3 2023.
- Funds reported $4.36B of Haemonetics stock for Q4 2023, down 4.1% quarter-over-quarter.
- 37 funds opened new Haemonetics positions in Q4 2023 and 36 closed out, a net change of +1 holder.
- The largest Haemonetics buyer in Q4 2023 was Morgan Stanley, an estimated $32.5M added.
- The largest Haemonetics seller in Q4 2023 was Millennium Management, an estimated $16M sold.
Based on aggregated 13F filings for Q4 2023.